Corvus Pharmaceuticals
CRVS
53 hedge funds and large institutions have $250M invested in Corvus Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 0 closing their positions.
83.62% more ownership
Funds ownership: 0% → 83.62% (+84%)
18% more funds holding
Funds holding: 45 → 53 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
7% less capital invested
Capital invested by funds: $267M → $250M (-$17.4M)
Top Buyers
Top Sellers
CRVS Hedge Fund Activity: Q4 2016 in Review
53 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2016, worth a combined $250M — down 6.5% from $267M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CRVS positions and 0 closed out — a net gain of 9 holders — while 15 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $19.4M. The largest seller was BlackRock Advisors, cutting an estimated $6.51M.
- 53 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2016, up from 45 in Q3 2016.
- Funds reported $250M of Corvus Pharmaceuticals stock for Q4 2016, down 6.5% quarter-over-quarter.
- 9 funds opened new Corvus Pharmaceuticals positions in Q4 2016 and 0 closed out, a net change of +9 holders.
- The largest Corvus Pharmaceuticals buyer in Q4 2016 was Fidelity Investments, an estimated $19.4M added.
- The largest Corvus Pharmaceuticals seller in Q4 2016 was BlackRock Advisors, an estimated $6.51M sold.
Based on aggregated 13F filings for Q4 2016.